Antidepressants, particularly SSRIs, do appear to reduce fertility in women, though the effect is moderate rather than dramatic. In one large prospective study, SSRI use was associated with a 24% reduction in the chance of conceiving in a given cycle. That doesn’t mean pregnancy is impossible, but it may take longer, and the mechanisms behind this delay are becoming clearer.
How Much Longer It May Take to Conceive
Researchers measure fertility impact using something called fecundability, which is essentially your probability of conceiving in any given menstrual cycle. In a study published in Fertility and Sterility, women with urinary markers of SSRI exposure had roughly 24% lower fecundability than unexposed women, along with a 9% lower rate of live birth overall. Women taking fluoxetine (Prozac) specifically showed a significantly lower live birth rate.
A separate analysis looking at cycle-by-cycle data found an even stronger signal. In any given cycle where a woman was actively taking an antidepressant, her chance of conceiving was about 34% lower than in cycles without antidepressant use. Importantly, this association held up even after researchers accounted for the woman’s history of depression or anxiety, suggesting the medication itself plays a role beyond the underlying condition.
One reassuring finding: researchers did not find differences in menstrual cycle regularity or length between women using and not using antidepressants. So the effect on fertility doesn’t necessarily show up as an obvious change in your period.
What Antidepressants Do Inside the Ovaries
The fertility impact appears to work through at least two pathways. The first involves hormones. SSRIs and other antidepressants with serotonin activity can cause a mild increase in prolactin, the hormone best known for triggering milk production. Even modestly elevated prolactin disrupts the normal pulsing of reproductive hormones that trigger ovulation. The result can be subtle: you might still get a period on schedule but occasionally fail to release an egg.
SSRIs also appear to suppress two key hormones, FSH and LH, through their effect on serotonin signaling in the brain. These hormones are the signals your brain sends to your ovaries to grow and release eggs each month. When those signals are dampened, ovulation can become less reliable.
The second pathway is more direct and was only recently identified. Animal research published in Pharmaceuticals found that fluoxetine nearly eliminated serotonin accumulation inside growing eggs. This matters because oocytes (eggs) actively take up serotonin as part of their maturation process. When that transport is blocked by an SSRI, it disrupts communication between the egg and its surrounding support cells, reducing what researchers call “oocyte competence,” meaning the egg’s ability to develop normally after fertilization. In adult mice, fluoxetine treatment shifted the ratio of eggs toward lower-quality types with poorer developmental potential.
Depression Itself vs. the Medication
This is the question most women trying to conceive really need answered: is it the depression hurting my fertility, or the pill I take for it? The data suggest it’s primarily the medication. Women with a history of depression who were not taking antidepressants had virtually identical fertility to women with no depression history. Their fecundability ratio was 1.03, meaning statistically no difference at all.
When researchers restricted their analysis only to women with a history of anxiety or depression, those actively taking antidepressants still had about 36% lower per-cycle conception rates than those managing without medication. That’s a meaningful gap, and it points to a pharmacological effect rather than a consequence of mood disorders themselves.
This doesn’t mean stopping your medication is the right call. Untreated or undertreated depression carries its own risks for both the person trying to conceive and a future pregnancy. The clinical consensus, reflected in ACOG’s 2023 guidance, is that the minimal reproductive risk associated with antidepressants may be well worth it when weighed against the consequences of unmanaged depression.
Which Medications Are Considered Safest
Not all antidepressants carry the same profile. Clinical guidelines favor sertraline (Zoloft) as a reasonable first-line choice for women in the preconception period. If you haven’t been on medication before and need to start one, sertraline and escitalopram (Lexapro) are considered relatively safe options that can be continued into pregnancy if needed.
Paroxetine (Paxil) is one clinicians specifically recommend switching away from before conception, due to concerns about birth defects. MAOIs, an older class of antidepressant, are contraindicated in pregnancy entirely because of risks including birth defects, restricted fetal growth, and dangerous blood pressure spikes.
SNRIs like venlafaxine (Effexor) show more variable effects. Their impact on reproductive hormones appears to depend on where you are in your menstrual cycle, and the research is less definitive than it is for SSRIs. Bupropion (Wellbutrin), which works on different brain chemicals than SSRIs, also shows cycle-phase-dependent behavior, though its fertility impact is not as well studied.
The general clinical approach is to use monotherapy (a single medication) at the lowest effective dose. This minimizes side effects, including reproductive ones, while still keeping depression managed.
What to Expect if You Stop
There is surprisingly little research on exactly how quickly fertility recovers after discontinuing antidepressants. Unlike hormonal birth control, where recovery timelines have been well mapped, no large studies have tracked how long it takes for prolactin levels, ovulatory hormones, and egg quality to normalize after stopping an SSRI or SNRI. The hormonal changes SSRIs cause tend to be modest, which suggests recovery is likely faster than, say, coming off injectable contraceptives. But that remains an educated assumption rather than a data-backed timeline.
What is well documented is the risk of depressive relapse after discontinuation. If you’re considering stopping your antidepressant to improve your chances of conceiving, that decision works best as a planned transition with your prescriber, ideally with a support strategy like cognitive behavioral therapy in place. Abruptly stopping carries both mental health risks and withdrawal symptoms that can add stress during an already emotionally charged time.
Putting the Numbers in Perspective
A 24% to 34% reduction in per-cycle conception odds sounds alarming, but it helps to put it in context. For a healthy couple in their late twenties, the baseline chance of conceiving in any single cycle is roughly 20% to 25%. A 24% reduction would bring that down to about 15% to 19% per cycle. You’re not looking at infertility. You’re looking at a longer timeline, potentially a few extra months of trying.
The effect also appears to be cycle-specific. The data showing reduced conception odds were strongest when looking at cycles where the woman was actively taking medication, rather than measuring a lasting effect from past use. This suggests the impact is pharmacologically active, not permanently damaging to reproductive tissue.
For women undergoing IVF or other assisted reproduction, the picture is less clear. The available research has focused primarily on natural conception, and dedicated studies on antidepressant use during fertility treatment cycles are limited. If you’re heading into IVF, this is worth discussing with your reproductive endocrinologist alongside your mental health provider.